Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 15/20 | 1.00 |
| ▸ | CTSL | P07711 | 3/20 | 1.00 |
| ▸ | CTSB | P07858 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CTSG | P08311 | 1/20 | 1.00 |
| ▸ | CAPN9 | O14815 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aloxistatin SCHEMBL12620387 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL21981208 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL21981210 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL18498407 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL483320 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL22273610 | 0.93 | CAPN1 (0.87) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL9314220 | 0.93 | CAPN1 (0.86) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL12653864 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL1804811 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL12653616 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| US-20230233510-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CORONAVIRUS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-07-27 | — | — | US | disclosed |
| US-9739767-B2 | Method of screening for plant defense activators, plant defense activators, and method of enhancing immune response | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20150141252-A1 | Method of Screening for Plant Defense Activators, Plant Defense Activators, and Method of Enhancing Immune Response | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2015-05-21 | — | — | US | disclosed |
| WO-2012029539-A1 | METHOD OF SCREENING FOR PLANT DEFENSE ACTIVATORS, PLANT DEFENSE ACTIVATORS, AND METHOD OF ENHANCING IMMUNE RESPONSE | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141252-A1 | Method of Screening for Plant Defense Activators, Plant Defense Activators, and Method of Enhancing Immune Response | NFATC1, TRAF6, STING1 | CAPN1 3373/4885CTSL 3517/4885CTSB 2327/4885 |
| US-20230233510-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CORONAVIRUS | ACE, PRSS1, CPA1 | CAPN1 83/4885CTSL 28/4885CTSB 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.